Skin advanced glycation end products in HIV infection are increased and predictive of development of cardiovascular events

Medicine and Dentistry

• Human Immunodeficiency Virus Infection 100%
• Autofluorescence 100%
• Advanced Glycation End-Product 100%
• Cardiovascular System 100%
• Cardiovascular Disease 72%
• Chronic Kidney Disease 27%
• Human Immunodeficiency Virus 18%
• Cell Count 18%
• Regression Analysis 18%
• Diabetes 9%
• Diabetes Mellitus 9%
• Volunteer 9%
• Prospective Cohort Study 9%
• Glycemic 9%
• Proportional Hazards Model 9%
• Oxidative Stress 9%
• Antiretroviral Therapy 9%
• Men Who Have Sex with Men 9%
• Human Immunodeficiency Virus 1 Infection 9%
• Hypertension 9%
• Median Follow Up 9%

Keyphrases

• HIV Infection 100%
• Cardiovascular Events 100%
• Skin Autofluorescence 100%
• Skin Advanced Glycation End-products 100%
• Chronic Kidney Disease 27%
• Advanced Glycation End Products 18%
• Nadir CD4 Cell Count 18%
• HIV-infected Patients 18%
• Prospective Cohort Study 9%
• Oxidative Stress 9%
• Regression Analysis 9%
• Healthy Volunteers 9%
• HIV-1 Infection 9%
• Single Center 9%
• Combined Antiretroviral Therapy (cART) 9%
• Cox Regression Analysis 9%
• Diabetic Kidney Disease 9%
• Subclinical Cardiovascular Disease 9%
• Patient Self-testing 9%
• Diabetes Mellitus 9%
• 95% Confidence Interval 9%
• Age-matched 9%
• Diabetes-hypertension 9%
• Cardiovascular Risk Factors 9%
• Stable Marker 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Human Immunodeficiency Virus Infection 100%
• Advanced Glycation End Product 100%
• Cardiovascular Disease 100%
• Chronic Kidney Failure 37%
• HIV 25%
• Diabetes Mellitus 12%
• Normal Human 12%
• Prospective Cohort Study 12%
• Human Immunodeficiency Virus 1 Infection 12%
• Hypertension 12%